Compare CNTN & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNTN | ANIK |
|---|---|---|
| Founded | 2017 | 1983 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.3M | 198.9M |
| IPO Year | 2022 | 1996 |
| Metric | CNTN | ANIK |
|---|---|---|
| Price | $3.58 | $14.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 441.5K | 91.7K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $112,819,000.00 |
| Revenue This Year | N/A | $5.98 |
| Revenue Next Year | N/A | $7.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.89 | $7.90 |
| 52 Week High | $5.27 | $16.24 |
| Indicator | CNTN | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 50.46 |
| Support Level | $3.01 | $13.95 |
| Resistance Level | $3.82 | $15.01 |
| Average True Range (ATR) | 0.24 | 0.54 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 69.47 | 42.76 |
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.